Know more

Our use of cookies

Cookies are a set of data stored on a user’s device when the user browses a web site. The data is in a file containing an ID number, the name of the server which deposited it and, in some cases, an expiry date. We use cookies to record information about your visit, language of preference, and other parameters on the site in order to optimise your next visit and make the site even more useful to you.

To improve your experience, we use cookies to store certain browsing information and provide secure navigation, and to collect statistics with a view to improve the site’s features. For a complete list of the cookies we use, download “Ghostery”, a free plug-in for browsers which can detect, and, in some cases, block cookies.

Ghostery is available here for free: https://www.ghostery.com/fr/products/

You can also visit the CNIL web site for instructions on how to configure your browser to manage cookie storage on your device.

In the case of third-party advertising cookies, you can also visit the following site: http://www.youronlinechoices.com/fr/controler-ses-cookies/, offered by digital advertising professionals within the European Digital Advertising Alliance (EDAA). From the site, you can deny or accept the cookies used by advertising professionals who are members.

It is also possible to block certain third-party cookies directly via publishers:

Cookie type

Means of blocking

Analytical and performance cookies

Realytics
Google Analytics
Spoteffects
Optimizely

Targeted advertising cookies

DoubleClick
Mediarithmics

The following types of cookies may be used on our websites:

Mandatory cookies

Functional cookies

Social media and advertising cookies

These cookies are needed to ensure the proper functioning of the site and cannot be disabled. They help ensure a secure connection and the basic availability of our website.

These cookies allow us to analyse site use in order to measure and optimise performance. They allow us to store your sign-in information and display the different components of our website in a more coherent way.

These cookies are used by advertising agencies such as Google and by social media sites such as LinkedIn and Facebook. Among other things, they allow pages to be shared on social media, the posting of comments, and the publication (on our site or elsewhere) of ads that reflect your centres of interest.

Our EZPublish content management system (CMS) uses CAS and PHP session cookies and the New Relic cookie for monitoring purposes (IP, response times).

These cookies are deleted at the end of the browsing session (when you log off or close your browser window)

Our EZPublish content management system (CMS) uses the XiTi cookie to measure traffic. Our service provider is AT Internet. This company stores data (IPs, date and time of access, length of the visit and pages viewed) for six months.

Our EZPublish content management system (CMS) does not use this type of cookie.

For more information about the cookies we use, contact INRA’s Data Protection Officer by email at cil-dpo@inra.fr or by post at:

INRA
24, chemin de Borde Rouge –Auzeville – CS52627
31326 Castanet Tolosan CEDEX - France

Dernière mise à jour : Mai 2018

Menu Logo Principal Oniris

Home page

Lhermie Guillaume

Early treatment of bovine respiratory disease with a decreased marbofloxacin regimen

Abstract :

The use of antibiotics in veterinary medicine may lead to selection of resistant bacteria, potentially transmissible to humans. Our study aimed at assessing under field conditions the effectiveness of early treatment of bovine respiratory disease (BRD) with a reduced dose of marbofloxacin, and its impact on (i) the amount of antibiotics consumed, and (ii) the selection of resistant commensal bacteria in the digestive tract. Preliminary experimental studies (in vitro and in animal models - mice and calf) allowed to validate the effectiveness of a reduced dose and to determine its conditions of use. During the field study, cattle were monitored using devices measuring their ruminal temperature, which increase constitutes an early sign of disease. In comparison with the administration of the 10 mg/kg dose recommended by the manufacturer, a unique early treatment with2 mg/kg marbofloxacin, before the onset of clinical signs, did reduce overall antibiotic consumption at the batch or farm level, despite an increase in the number of administered treatments. Whatever the dose, the impact of marbofloxacin on selecting commensal bacteria proved limited in calves and young cattle. Finally, our work highlights through the case of BRD, the possible reduction of the use of antibiotics in bovine medicine. To achieve this, the development of a veterinary precision medicine, combining monitoring and diagnosis tools with adjusted medication protocols, should be encouraged.

Key words :

Cattle, bovine respiratory disease, fluoroquinolone, early treatment, decreased regimen, antimicrobial resistance, precision medicine